Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.49 |
| ▸ | CDC42BPB | Q9Y5S2 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.46 |
| ▸ | TPX2 | Q9ULW0 | 3/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26175331 | 0.83 | PDPK1 (0.52) | MAPK1PDPK1 | |
| SCHEMBL26176226 | 0.81 | MAPT (0.53) | ROCK2ROCK1CDC42BPBMAPK1AURKA | |
| SCHEMBL16835978 | 0.80 | ROCK2 (0.62) | ROCK2ROCK1CDC42BPBMAPK1AURKA | |
| SCHEMBL25518134 | 0.79 | LRRK2 (0.45) | ROCK2ROCK1CDC42BPBMAPK1CDC42BPA | |
| SCHEMBL30348045 | 0.79 | LRRK2 (0.45) | ROCK2ROCK1CDC42BPBMAPK1CDC42BPA | |
| SCHEMBL26174581 | 0.76 | CDK5 (0.55) | ROCK2ROCK1CDC42BPBMAPK1AURKB | |
| SCHEMBL16854189 | 0.76 | ROCK2 (0.62) | ROCK2ROCK1CDC42BPBMAPK1AURKA | |
| SCHEMBL16835899 | 0.75 | ROCK2 (0.56) | ROCK2ROCK1CDC42BPBMAPK1AURKA | |
| SCHEMBL16854269 | 0.75 | ROCK2 (0.58) | ROCK2ROCK1CDC42BPBMAPK1AURKA | |
| SCHEMBL16854267 | 0.73 | ROCK2 (0.52) | ROCK2ROCK1CDC42BPBMAPK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | ROCK2 560/4885ROCK1 325/4885CDC42BPB 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.